Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB4211 Safety and PK in Healthy and NAFLD Subjects
NCT03998514Phase 1Completed
- Sponsor
- CohBar, Inc.
- Start
- Jul 2018
- Primary completion
- Apr 2021
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CB4211 in non-alcoholic fatty liver disease (NAFLD) (10 arms), sponsored by CohBar, Inc. Primary endpoints: Incidence and severity of adverse events at 12 weeks, Clinical laboratory evaluations at 5 weeks and 4 more. Started Jul 2018; status: completed.
02
Drugs
CB4211
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT03998514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03998514.